STADA Pharmaceuticals Australia
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From STADA Pharmaceuticals Australia
Amgen’s Bevacizumab Biosimilar Is Alone On Australia’s PBS
US-based giant Amgen has seen its Mvasi biosimilar become the sole bevacizumab product listed on Australia’s Pharmaceutical Benefits Scheme.
Takeda Sheds More Non-Core Assets, Employees In $670m Orifarm Deal
Danish firm picks up portfolio and manufacturing sites, along with around 600 employees.
Stada Launches Propofol Pump In Australia Via BioQ Tie-Up
Stada is looking to add value to Australia’s anesthetics market by introducing BioQ Pharma’s ready-to-use Propofusor propofol device.
Deals Shaping The Medical Industry, September 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.